Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth fa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Breast Cancer Res
Egile Nagusiak: Bianchini, Giampaolo, Kiermaier, Astrid, Bianchi, Giulia Valeria, Im, Young-Hyuck, Pienkowski, Tadeusz, Liu, Mei-Ching, Tseng, Ling-Ming, Dowsett, Mitch, Zabaglo, Lila, Kirk, Sarah, Szado, Tania, Eng-Wong, Jennifer, Amler, Lukas C., Valagussa, Pinuccia, Gianni, Luca
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299741/
https://ncbi.nlm.nih.gov/pubmed/28183321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0806-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak